Table 1.
Patient Characteristics (3994 Patients)
| Characteristics | Non-ONJ (N = 3965) | ONJ (N = 29) | p |
| Median age in (yr; minimum-maximum) | 60 (3–101) | 62 (43–82) | 0.60* |
| Sex [male/female (n)] | 1637/2328 | 8/21 | 0.18* |
| Cancer diagnosis (n) | |||
| Breast cancer | 1457† | 16 | |
| Multiple myeloma | 541‡ | 13 | |
| Renal cell carcinoma | 327 | 0 | |
| Lung cancer | 380 | 0 | |
| Prostate cancer | 185 | 0 | |
| Others | 1075 | 0 | |
| Indication for bisphosphonate therapy (n)§ | |||
| Bone metastases | 2392 | 16 | |
| Multiple myeloma | 535 | 13 | |
| Hypercalcemia | 1023 | 0 | |
| Osteoporosis | 271 | 0 | |
| Paget's disease | 11 | 0 | |
| Median years duration of disease (minimum-maximum) | 3.11 (0–46.04) | 5.75 (0.91–24.37) | 0.0001* |
| Median duration of follow-up (minimum-maximum) | 1.77 (0–36.45) | 5.39 (0.81–12.75) | <0.0001* |
| Bisphosphonate (n) | |||
| Pamidronate | 2281 | 7 | <0.0001¶ |
| Zoledronic acid | 1171 | 9 | |
| Pamidronate + zoledronic acid | 513 | 13 | |
| Median dose (mg) of bisphosphonate (minimum-maximum) | |||
| Pamidronate | 180 (13–9810) | 1755 (90–3510) | <0.0001* |
| Zoledronic acid | 12 (2–270) | 62 (8–152) | <0.0001* |
| Median duration of bisphosphonate treatment in years (minimum-maximum) | |||
| Pamidronate | 0.08 (0.003–8.43) | 1.67 (0.003–4.24) | <0.0001* |
| Zoledronic acid | 0.29 (0.003–4.07) | 2.02 (0.17–5.94) | <0.0001* |
| Dental extractions (yes/no) | 136/3829 | 16/13 | <0.0001¶ |
| Pamidronate use (yes/no) | 2794/1171 | 20/9 | 0.8400¶ |
| Zoledronic acid use (yes/no) | 1684/2281 | 22/7 | 0.0004¶ |
Duration of follow-up was defined as the time interval between first visit to last visit at our institution.
* p values were calculated with the use of the Wilcoxon rank-sum test.
† The total number of breast cancer patients without ONJ was 1457 (1322 treated with bisphosphonates for bone metastases and 135 treated for osteoporosis).
‡ The total number of patients with myeloma without ONJ was 541 (535 treated with bisphosphonates for myeloma bone disease and 6 treated for osteoporosis).
§ A few patients had more than one indication for bisphosphonate therapy.
¶ p values were calculated with the use of the Fisher's exact test to examine the association of dental extraction, pamidronate use and zoledronic acid use with development of ONJ.